SOMERSET, N.J., July 26 /PRNewswire-FirstCall/ -- Alfacell Corporation and US Pharmacia today announced that Alfacell has entered into a distribution agreement with USP Pharma Spolka Z.O.O. (USP Pharma), an affiliate of US Pharmacia, for the commercialization of ONCONASE(R) (ranpirnase), Alfacell's lead drug candidate, in Eastern Europe. ONCONASE is currently being evaluated as a treatment for unresectable malignant mesothelioma (UMM) in a confirmatory Phase IIIb registration study.

Read the full announcement here...